Common Sensing

Develops a noninvasive wearable for blood glucose monitoring that uses measurements of combined LED and infrared wavelengths Company's revenue model is based on device sales and technology licensing; estimated target price is USD 225 for the device Company is also looking for partners that are interested in embedding its optical sensor technology into an end-user product Does not have regulatory clearance, but is preparing to conduct clinical trials, potentially to obtain class II medical U.S. FDA clearance Dia-Vit is one of an emerging number of noninvasive glucose-sensing developers, but like others in this space, clients should wait and see if Dia-Vit can deliver on its claims

Core technology is based on the analysis of small, involuntary eye movements that happen in response to cognitive changes; can be applied to diagnostic of attention-deficit/hyperactivity disorder (ADHD) and other cognitive disorders Eye-tracking cameras are placed behind the computer monitor's screen and are capable of detecting rapid eye movement with subdegree accuracy Data analytics is done in the cloud, and generated PDF reports are available to doctors within minutes Competing solutions that rely on electroencephalography (EEG) measurements and motion detection do not approach diagnostic-grade sensitivity, especially in psychiatric patient populations Unique eye-tracking technology for the diagnosis and monitoring of a variety of cognitive disorders provides a solid platform for growth; success will depend on the ability to demonstrate cost effectiveness and clinical outcome improvements

The company develops a digital therapeutic solution based on rhythmic auditory stimulation (RAS) comprising shoe-worn sensors for gait detection, a music player, and headphones Differentiated by the digitization of this therapy, as RAS is traditionally performed in person by a licensed practitioner, the company makes the treatment available to a broader segment of the population MedRhythms is further differentiated by a music modulation platform that can take any piece of music the patient wishes and alter it to match their therapeutic needs MedRhythms is planning an initial product targeting post-stroke rehabilitation, with a two-to-five-year plan for developing future products focused on aging in place, neurodegenerative disease, and traumatic brain injury, with its key performance indicator being an improvement in gait The company may run into issues finding providers qualified to administer such a therapy, but the solution itself is well differentiated Consumer pacakged goods and material clients should look to MedRhythms as a potential partner in the codevelopment of new and innovative insoles for different market segments needing its solution